Triglycerides: Emerging Targets in Diabetes Care? Review of Moderate Hypertriglyceridemia in Diabetes.

Journal Article (Journal Article;Review)

PURPOSE OF REVIEW: Moderate hypertriglyceridemia is exceedingly common in diabetes, and there is growing evidence that it contributes to residual cardiovascular risk in statin-optimized patients. Major fibrate trials yielded inconclusive results regarding the cardiovascular benefit of lowering triglycerides, although there was a signal for improvement among patients with high triglycerides and low high-density lipoprotein (HDL)-the "diabetic dyslipidemia" phenotype. Until recently, no trials have examined a priori the impact of triglyceride lowering in patients with diabetic dyslipidemia, who are likely among the highest cardiovascular-risk patients. RECENT FINDINGS: In the recent REDUCE IT trial, omega-3 fatty acid icosapent ethyl demonstrated efficacy in lowering cardiovascular events in patients with high triglycerides, low HDL, and statin-optimized low-density lipoprotein (LDL). The ongoing PROMINENT trial is examining the impact of pemafibrate in a similar patient population. Emerging evidence suggests that lowering triglycerides may reduce residual cardiovascular risk, especially in high-risk patients with diabetic dyslipidemia.

Full Text

Duke Authors

Cited Authors

  • Alexopoulos, A-S; Qamar, A; Hutchins, K; Crowley, MJ; Batch, BC; Guyton, JR

Published Date

  • February 26, 2019

Published In

Volume / Issue

  • 19 / 4

Start / End Page

  • 13 -

PubMed ID

  • 30806837

Pubmed Central ID

  • PMC6664805

Electronic International Standard Serial Number (EISSN)

  • 1539-0829

Digital Object Identifier (DOI)

  • 10.1007/s11892-019-1136-3


  • eng

Conference Location

  • United States